New progress on the use of Dual Biologic Therapy for patients with Inflammatory Bowel Disease
10.3760/cma.j.cn101721-20230317-000097
- VernacularTitle:双重生物制剂疗法在炎症性肠病患者治疗中的研究进展
- Author:
Yuhang LIU
1
;
Haiying ZHAO
;
Ye ZONG
Author Information
1. 首都医科大学附属北京友谊医院消化内科 国家消化疾病临床医学研究中心 北京消化疾病中心，北京 100050
- Keywords:
Biological agents;
Dual biologic therapy;
Inflammatory bowel disease;
Ulcerative colitis;
Crohn's disease
- From:
Clinical Medicine of China
2023;39(3):206-211
- CountryChina
- Language:Chinese
-
Abstract:
At present, the incidence of inflammatory bowel disease in China is increasing. Although new biological agents continue to emerge, which induce a higher clinical remission rate in moderate and severe patients than traditional drugs and have much advantages in reducing the risk of surgery and changing the natural history, the remission rate of biological agents monotherapy is still not enough. In this context, dual biologic therapy is a viable strategy. Dual biologic therapy is mainly indicated for patients with inflammatory bowel disease that is refractory or complicated with extraintestinal manifestations.It is often used in combination with clinical practice according to the characteristics of drugs, showing relatively great efficacy and safety, but a series of key questions still need a high level of research evidence to explore.
